Moreover, tirzepatide’s engagement with GIPR in adipose and pancreatic tissue contributes to enhanced metabolic flexibility and β-cell preservation, highlighting its advantage as a multi-target agent for obesity [186,189]. Here, GIPR is linked to obesity due to melanocortin 4 receptor deficiency.